X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, ...
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...
Clinical Trials Arena on MSN
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win
Analysts are encouraged by azetukalner’s differentiated MoA and efficacy in epilepsy, as well as the lack of titration needed when prescribing the drug.
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...
March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...
Xenon Pharmaceuticals Inc. XENE-Q generated positive results from a critical late-stage human trial for its epilepsy ...
Xenon Pharmaceuticals Inc. XENE shares are up during Monday’s premarket session following the announcement of positive ...
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for ...
Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...
Xenon Pharmaceuticals shares rose after the company said it received positive data from its study of its investigational treatment for focal onset seizures. Shares rose 46.5% to $61.45.
Biohaven Ltd BHVN shares were trading higher on Monday during the premarket session at as high as $12.52, before falling. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results